UroGen Pharma URGN Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about UroGen Pharma's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is UroGen Pharma's accrued expenses?
- UroGen Pharma (URGN) reported accrued expenses of $9.84M in Q1 2026.
- How has UroGen Pharma's accrued expenses changed year-over-year?
- UroGen Pharma's accrued expenses increased by 41.2% year-over-year, from $6.97M to $9.84M.
- What is the long-term trend for UroGen Pharma's accrued expenses?
- Over 5 years (2020 to 2025), UroGen Pharma's accrued expenses has grown at a 7.2% compound annual growth rate (CAGR), from $9.55M to $13.52M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.